Under the agreement, Cyclotek will produce and provide doses of Tb-labeled RAD 402 to support Radiopharm's upcoming Phase 1 clinical trial in prostate cancer in Australia. The Phase 1 trial is anticipated to start in the second half of 2025. RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025 SYDNEY and BUNDOORA, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Radiopharm T ...

New York, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Mixed Martial Arts Group Limited (NYSE American: MMA) ("MMA" or the "Company") a technology-driven company focused on transforming consumer engagement in martial arts and combat sports, today announced that its Founder and CEO, Nick Langton, and Chairman of the Board, Vaughn Taylor, have each converted $125,000 for a total of $250,000 in loans previously provided to the Company into common equity. MMA.INC (Mixed Martial Arts Group Limited) is revolutionizing t ...

Within the family program agenda, Aardvark's Chief Medical Officer, Manasi Jaiman, M.D., will join a panel of clinicians to discuss the details of the company's ongoing Phase 3 HERO study. Additional members of the company's medical and advocacy team invite the medical community and families attending to engage with attending team members at the company's booth to learn more about ARD-101, the HERO study and the company's commitment to the PWS community. SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark ...

TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,128,012, expiring May 14, 2041, for the use of ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS). This newly issued patent significantly strengthens the Company's intellectual propert ...

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000 and Russell 2000 Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution. The Russell 3000 Index tracks the performance of the la ...

文章核心观点 - 东南亚领先社区电商和旅游平台Webuy Global Ltd.宣布任命Heng Wee Koon为独立董事兼薪酬委员会主席 强调其资历和战略价值 [1] 公司任命 - 公司宣布任命Heng Wee Koon为独立董事兼薪酬委员会主席 [1] 被任命人资历 - Heng Wee Koon拥有超25年并购、财务咨询和公司治理领导经验 [2] - 他现任Hyphens Pharma International Ltd.首席独立董事 该公司在其领导下获2024年新加坡企业奖最佳管理董事会金奖 [2] - 他曾是毕马威咨询合伙人 创立并购咨询公司Acelyr M&A和Acelyr Advisory [3] - 他拥有新加坡国立大学荣誉工商管理学士、南京大学工商管理硕士学位 是CFA持证人及新加坡董事学会高级认证董事 [4] 公司评价 - 公司CEO表示Heng Wee Koon在公司治理和战略咨询方面的专业知识对公司扩大规模很有价值 [4] - 他的广泛人脉、跨境交易经验及对并购和企业增长战略的深刻见解将推动新扩张机会 创造股东价值 支持公司长期可持续增长 [4] 公司简介 - 公司是技术驱动型企业 利用预测性AI、个性化推荐和社区参与提升团购模式 旅游业务通过专有AI旅游顾问提供定制行程和实时支持 [5] - 公司致力于提供高质量、实惠的产品和旅游服务 改善东南亚数百万人生活 [5]

Please call the conference telephone number 10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 949-574-3860. The conference call will be broadcast live and available for replay here and via the Investor Relations section of Byrna's website. ANDOVER, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. ("Byrna" or the "Company") (Nasdaq: BYRN), a personal defense ...

Meet zSpace's Educator of the Year, Explore What's New, and Experience Our Latest Elementary Solution, Imagine SAN JOSE, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- zSpace (NASDAQ: ZSPC) ("zSpace" or the "Company"), a leading provider of augmented and virtual reality solutions for education, today announced its participation in the ISTE Live 25 Conference, taking place June 30–July 2 at the Henry B. González Convention Center in San Antonio, Texas. The Company invites attendees to visit Booth #1948 for three ...

Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity’s Broader Profitability and Growth Objectives DUBLIN, June 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received World Health ...

文章核心观点 公司全资子公司Terronera修订并重述高级有担保债务融资安排，增加信贷额度，用于项目调试和运营资金，同时采取银价风险管理措施，项目调试按计划进行 [1][2][3] 相关要点总结 信贷安排 - 公司全资子公司Terronera与ING Capital LLC和法国兴业银行修订并重述高级有担保债务融资安排，信贷额度从1.2亿美元增加1500万美元至1.35亿美元 [1][2] - 信贷资金用于完成墨西哥哈利斯科州Terronera项目调试和一般营运资金 [2] 风险管理 - Terronera为管理银价风险和现金流，签订零成本区间协议，在未来12个月内为约96.8万盎司白银提供每盎司31美元的下行保护，并参与每盎司最高42美元的银价上涨收益 [3] 项目进展 - Terronera项目调试活动按计划进行，符合管理层预期，公司将在商业生产开始前提供最新情况 [4] 公司概况 - 公司是一家中型贵金属公司，致力于可持续和负责任的采矿实践，在墨西哥和秘鲁有业务，正在开发哈利斯科州新的基石矿，还有墨西哥、智利和美国的勘探项目组合，目标是成为顶级白银生产商 [5]